Kenvue Inc. is expected to report Q3 2026 revenue of $3.93 billion and EPS of $0.28, with the current stock price of $25.12 trading below the average analyst target of $27.40. Investors are primarily focused on the organic growth rate within the Skin Health and Beauty segment, which has recently faced market share pressures.
Analysts are looking for signs that increased marketing expenditures and product innovation are finally stabilizing core brands like Neutrogena. Furthermore, the market will be evaluating management’s ability to sustain margins in the face of persistent raw material inflation and competitive pricing environments.